Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

Globally, cardiovascular diseases (CVDs) account for around one-third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon-like peptide-1 (GLP-1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all-cause mortality. Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that has demonstrated dose-dependent efficacy in people with obesity, T2D or both, in terms of glycaemic control and bodyweight reduction in clinical trials. This narrative review summarizes the current evidence regarding the effects of tirzepatide treatment on cardiometabolic parameters, including lipid profile, blood pressure and markers of renal function. Additionally, it summarizes the reported impact of tirzepatide treatment on other relevant parameters, such as body composition, liver fat, progression to T2D among individuals with prediabetes, and incidence of heart failure events. Considering the changing landscape of clinical trial evidence of tirzepatide's effects, this review aims to compile the available evidence, which suggests a promising outlook for the cardiometabolic benefits of tirzepatide.